4.6 Article

Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma

Journal

BLOOD ADVANCES
Volume 7, Issue 13, Pages 3225-3231

Publisher

ELSEVIER
DOI: 10.1182/bloodadvances.2022009323

Keywords

-

Categories

Ask authors/readers for more resources

Through a retrospective analysis of 67 pediatric patients, it was found that brentuximab vedotin in combination with vedotin had good tolerability and a safety profile similar to that of adult patients in the treatment of relapsed/refractory Hodgkin lymphoma. With a median follow-up of 37 months, the 3-year progression-free survival was 85%. These data suggest a potential role for the use of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in children with relapsed/refractory Hodgkin lymphoma.
Outcomes for children and adolescents with relapsed and refractory Hodgkin lymphoma (HL) are poor, with similar to 50% of patients experiencing a subsequent relapse. The anti-CD30 antibody-drug conjugate brentuximab vedotin improved progression-free survival (PFS) when used as consolidation after autologous stem cell transplantation (ASCT) in adults with high-risk relapsed/refractory HL. Data on brentuximab vedotin as consolidative therapy after ASCT in pediatric patients with HL are extremely limited, with data of only 11 patients reported in the literature. We performed a retrospective analysis of 67 pediatric patients who received brentuximab vedotin as consolidation therapy after ASCT for the treatment of relapsed/refractory HL to describe the experience of this regimen in the pediatric population. This is the largest cohort reported to date. We found that brentuximab vedotin was well tolerated with a safety profile similar to that of adult patients. With a median follow-up of 37 months, the 3-year PFS was 85%. These data suggest a potential role for the use of brentuximab vedotin as consolidation therapy after ASCT for children with relapsed/refractory HL.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available